Genelux Investor Presentation Deck

Demonstrated Deep and Durable Tumor Shrinkage Tumor Shrinkage Key Clinical Takeaways Refractory patients performed as well as resistant patients Tumor Shrinkage Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction ● Four patients had 100% reduction target lesions (two with confirmed CR), including two platinum-refractory patients Duration of Response (DOR) DOR of 7.6 Months in all platinum- ● Resistant patients DOR of 8.0 Months in platinum- refractory patients GENELUX Change of target lesion size (% change of SLD) Best change of target lesions from baseline (%) 100 80 60 40 20 60 40 20 -20 -40 -20 -40 -30% partial response -60 -80 -100 -60 -80 15A-18 -100 15B-09 158-19 15A-19 15A-27 E-POS 120 platinum-resistant platinum-refractory 15B-18 15A-06 15A-30 180 SA-2 158-01 15A-29 240 Duration of Response Baseline tumor burden as Sum of Longest Diameter of target lesions (mm) 15A-05 Time (days) 300 15A-37 158-17 360 15A-22 15A-16 SA-0 PD OR (CR or PR) SD 420 15A-25 480 158-15 15A-31 SA-3 540 -30% partial response 14

View entire presentation